Antibodies to MOG have a demyelination phenotype and affect oligodendrocyte cytoskeleton

Neurology: Neuroimmunology and NeuroInflammation

Volumn 1, Issue 1, 2014, Pages

  Dale, Russell C ^a   Tantsis, Esther M ^a   Merheb, Vera ^a   Kumaran, Raani Yogeeta A ^a   Sinmaz, Nese ^a   Pathmanandavel, Karrnan ^a   Ramanathan, Sudarshini ^a   Booth, David R ^a   Wienholt, Louise A ^b   Prelog, Kristina ^c   Clark, Damien R ^d   Guillemin, Gilles J ^e   Lim, Chai K ^e   Mathey, Emily K ^a   Brilot, Fabienne ^a  

^a UNIVERSITY OF SYDNEY   (Australia)

^b ROYAL PRINCE ALFRED HOSPITAL   (Australia)

^c CHILDREN S HOSPITAL AT WESTMEAD   (Australia)

^d WOMEN S AND CHILDREN S HOSPITAL   (Australia)

^e MACQUARIE UNIVERSITY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

2',3' CYCLIC NUCLEOTIDE 3' PHOSPHODIESTERASE; AQUAPORIN 4 ANTIBODY; BETA TUBULIN; BIOLOGICAL MARKER; F ACTIN; GALACTOSYLCERAMIDE; HLA DRB1 ANTIGEN; MYCOPHENOLATE MOFETIL; MYELIN BASIC PROTEIN; MYELIN OLIGODENDROCYTE GLYCOPROTEIN ANTIBODY; PROTEIN ANTIBODY; UNCLASSIFIED DRUG; VIMENTIN;

ADOLESCENT; ANTIBODY LABELING; ARTICLE; BRAIN STEM; CHILD; CHILDHOOD DISEASE; CLINICAL FEATURE; CONTROLLED STUDY; DEMYELINATING DISEASE; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; FLUORESCENCE ACTIVATED CELL SORTING; HETEROZYGOSITY; HOMOZYGOSITY; HUMAN; HUMAN CELL; IMMUNOSUPPRESSIVE TREATMENT; MAJOR CLINICAL STUDY; MALE; MICROTUBULE; NUCLEAR MAGNETIC RESONANCE IMAGING; OLIGODENDROGLIA; OPTIC NEURITIS; PHENOTYPE; PRIORITY JOURNAL; REMISSION; THIN FILAMENT; THREE DIMENSIONAL IMAGING;

EID: 84922955744     PISSN: None     EISSN: 23327812     Source Type: Journal    
DOI: 10.1212/NXI.0000000000000012     Document Type: Article

References (40)

1. Papadopoulos MC, Verkman AS. Aquaporin 4 and neuromyelitis optica. Lancet Neurol. 2012; 11: 535-544.
2. Vincent A, Bien CG, Irani SR, Waters P. Autoantibodies associated with diseases of the CNS: new developments and future challenges. Lancet Neurol. 2011; 10: 759-772.
3. Wingerchuk DM, Lennon VA, Lucchinetti CF, Pittock SJ, Weinshenker BG. The spectrum of neuromyelitis optica. Lancet Neurol. 2007; 6: 805-815.
4. Johns TG, Bernard CC. The structure and function of myelin oligodendrocyte glycoprotein. J Neurochem. 1999; 72: 1-9.
5. Linington C, Bradl M, Lassmann H, Brunner C, Vass K. Augmentation of demyelination in rat acute allergic encephalomyelitis by circulating mouse monoclonal antibodies directed against a myelin/oligodendrocyte glycoprotein. Am J Pathol. 1988; 130: 443-454.
6. Pollinger B, Krishnamoorthy G, Berer K, et al. Spontaneous relapsing-remitting EAE in the SJL/J mouse: MOG-reactive transgenic T cells recruit endogenous MOG-specific B cells. J Exp Med. 2009; 206: 1303-1316.
7. Schluesener HJ, Sobel RA, Linington C, Weiner HL A monoclonal antibody against a myelin oligodendrocyte glycoprotein induces relapses and demyelination in central nervous system autoimmune disease. J Immunol. 1987; 139: 4016-4021.
8. von Budingen HC, Hauser SL, Fuhrmann A, Nabavi CB, Lee JI, Genain CP. Molecular characterization of antibody specificities against myelin/oligodendrocyte glycoprotein in autoimmune demyelination. Proc Natl Acad Sci U S A. 2002; 99: 8207-8212.
9. Reindl M, Di Pauli F, Rostasy K, Berger T. The spectrum of MOG autoantibody-Associated demyelinating diseases. Nat Rev Neurol. 2013; 9: 455-461.
10. Brilot F, Dale RC, Selter RC, et al. Antibodies to native myelin oligodendrocyte glycoprotein in children with inflammatory demyelinating central nervous system disease. Ann Neurol. 2009; 66: 833-842.
11. Di Pauli F, Mader S, Rostasy K, et al. Temporal dynamics of anti-MOG antibodies in CNS demyelinating diseases. Clin Immunol. 2011; 138: 247-254.
12. Lalive PH, Hausler MG, Maurey H, et al. Highly reactive anti-myelin oligodendrocyte glycoprotein antibodies differentiate demyelinating diseases from viral encephalitis in children. Mult Scler. 2011; 17: 297-302.
13. McLaughlin KA, Chitnis T, Newcombe J, et al. Agedependent B cell autoimmunity to a myelin surface antigen in pediatric multiple sclerosis. J Immunol. 2009; 183: 4067-4076.
14. Rostasy K, Mader S, Schanda K, et al. Anti-myelin oligodendrocyte glycoprotein antibodies in pediatric patients with optic neuritis. Arch Neurol. 2012; 69: 752-756.
15. Zhou D, Srivastava R, Nessler S, et al. Identification of a pathogenic antibody response to native myelin oligodendrocyte glycoprotein in multiple sclerosis. Proc Natl Acad Sci U S A. 2006; 103: 19057-19062.
16. Mader S, Gredler V, Schanda K, et al. Complement activating antibodies to myelin oligodendrocyte glycoprotein in neuromyelitis optica and related disorders. J Neuroinflammation. 2011; 8: 184.
17. Tantsis EM, Prelog K, Brilot F, Dale RC. Risk of multiple sclerosis after a first demyelinating syndrome in an Australian Paediatric cohort: clinical, radiological features and application of the McDonald 2010 MRI criteria. Mult Scler. 2013; 19: 1749-1759.
18. Krupp LB, Tardieu M, Amato MP, et al. International Pediatric Multiple Sclerosis Study Group criteria for pediatric multiple sclerosis and immune-mediated central nervous system demyelinating disorders: revisions to the 2007 definitions. Mult Scler. 2013; 19: 1261-1267.
19. Aggarwal A, Iemma TL, Shih I, et al. Mobilization of HIV spread by diaphanous 2 dependent filopodia in infected dendritic cells. PLoS Pathog. 2012; 8: e1002762.
20. Amatoury M, Merheb V, Langer J, Wang XM, Dale RC, Brilot F. High-Throughput flow cytometry cell-based assay to detect antibodies to N-methyl-D-Aspartate receptor or dopamine-2 receptor in human serum. J Vis Exp. 2013; 81: e50935.
21. Brilot F, Merheb V, Ding A, Murphy T, Dale RC. Antibody binding to neuronal surface in Sydenham chorea, but not in PANDAS or Tourette syndrome. Neurology. 2011; 76: 1508-1513.
22. Dale RC, Merheb V, Pillai S, et al. Antibodies to surface dopamine-2 receptor in autoimmune movement and psychiatric disorders. Brain. 2012; 135: 3453-3468.
23. Mohammad SS, Sinclair K, Pillai S, et al. Herpes simplex encephalitis relapse with chorea is associated with autoantibodies to N-Methyl-D-Aspartate receptor or dopamine-2 receptor. Mov Disord. 2014; 29: 117-122.
24. Buntinx M, Vanderlocht J, Hellings N, et al. Characterization of three human oligodendroglial cell lines as a model to study oligodendrocyte injury: morphology and oligodendrocyte-specific gene expression. J Neurocytol. 2003; 32: 25-38.
25. Elliott C, Lindner M, Arthur A, et al. Functional identification of pathogenic autoantibody responses in patients with multiple sclerosis. Brain. 2012; 135: 1819-1833.
26. Mathey EK, Derfuss T, Storch MK, et al. Neurofascin as a novel target for autoantibody-mediated axonal injury. J Exp Med. 2007; 204: 2363-2372.
27. Marta CB, Montano MB, Taylor CM, Taylor AL, Bansal R, Pfeiffer SE. Signaling cascades activated upon antibody cross-linking of myelin oligodendrocyte glycoprotein: potential implications for multiple sclerosis. J Biol Chem. 2005; 280: 8985-8993.
28. Marta CB, Taylor CM, Coetzee T, et al. Antibody crosslinking of myelin oligodendrocyte glycoprotein leads to its rapid repartitioning into detergent-insoluble fractions, and altered protein phosphorylation and cell morphology. J Neurosci. 2003; 23: 5461-5471.
29. Brilot F, Strowig T, Roberts SM, Arrey F, Munz C. NK cell survival mediated through the regulatory synapse with human DCs requires IL-15Ralpha. J Clin Invest. 2007; 117: 3316-3329.
30. Australia and New Zealand Multiple Sclerosis Genetics Consortium (ANZgene). Genome-wide association study identifies new multiple sclerosis susceptibility loci on chromosomes 12 and 20. Nat Genet. 2009; 41: 824-830.
31. Kitley J, Woodhall M, Waters P, et al.Myelin-oligodendrocyte glycoprotein antibodies in adults with a neuromyelitis optica phenotype. Neurology. 2012; 79: 1273-1277.
32. Rostasy K, Mader S, Hennes EM, et al. Persisting myelin oligodendrocyte glycoprotein antibodies in aquaporin-4 antibody negative pediatric neuromyelitis optica. Mult Scler. 2013; 19: 1052-1059.
33. Probstel AK, Dornmair K, Bittner R, et al. Antibodies to MOG are transient in childhood acute disseminated encephalomyelitis. Neurology. 2011; 77: 580-588.
34. Stewart GJ, Teutsch SM, Castle M, Heard RN, Bennetts BH. HLA-DR, -DQA1 and -DQB1 associations in Australian multiple sclerosis patients. Eur J Immunogenet. 1997; 24: 81-92.
35. Waters P, Woodhall M, Hacohen Y, et al. Antibodies to myelin oligodendrocyte glycoprotein (MOG) in children and adults with demyelinating disorders (NMO). Ann Neurol. 2013; 74: S18-S19.
36. O Connor KC, McLaughlin KA, De Jager PL, et al. Selfantigen tetramers discriminate between myelin autoantibodies to native or denatured protein. Nat Med. 2007; 13: 211-217.
37. Waters PJ, McKeon A, Leite MI, et al. Serologic diagnosis of NMO: a multicenter comparison of aquaporin-4-IgG assays. Neurology. 2012; 78: 665-671.
38. Lalive PH, Menge T, Delarasse C, et al. Antibodies to native myelin oligodendrocyte glycoprotein are serologic markers of early inflammation in multiple sclerosis. Proc Natl Acad Sci U S A. 2006; 103: 2280-2285.
39. Dyer CA, Matthieu JM. Antibodies to myelin/oligodendrocytespecific protein and myelin/oligodendrocyte glycoprotein signal distinct changes in the organization of cultured oligodendroglial membrane sheets. J Neurochem. 1994; 62: 777-787.
40. Mayer MC, Breithaupt C, Reindl M, et al. Distinction and temporal stability of conformational epitopes on myelin oligodendrocyte glycoprotein recognized by patients with different inflammatory central nervous system diseases. J Immunol. 2013; 191: 3594-3604.